Document:

Original Equipment Manufacturers Agreement

 [CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THE AGREEMENT HAVE BEEN REDACTED AND SEPARATELY
FILED WITH THE COMMISSION.] 
  
  
 Exhibit 10.22 
  
 Andor Technology Ltd.            Original Equipment Manufacturer Agreement 
  
  
 

 
  
 Original Equipment
Manufactures (OEM) Agreement with 
  
 Xenogen Corporation

  

					
	Confidential	 	Page 1	 	July 26, 2002

 Andor Technology
Ltd.            Original Equipment Manufacturer Agreement 
  
 DATED 20th of September
2002 
  
 ANDOR TECHNOLOGY LIMITED (“the Manufacturer”) 
  
 -with- 
  
 Xenogen Corporation (“the OEM”) 
 860 Atlantic Ave. Alameda, CA 94501 
  

					
	Confidential	 	Page 2	 	July 26, 2002

 Andor Technology
Ltd.            Original Equipment Manufacturer Agreement 
  
 OEM AGREEMENT 
  

							
	 AN AGREEMENT
	 	made 20th, September 2002
				
	 BETWEEN
	 	 	 	 	 	 
		
	 (“the Manufacturer”)
	 	ANDOR TECHNOLOGY LIMITED a company incorporated in Northern Ireland under number N122466 having its registered office at 9 Millennium Way, Springvale Business Park, Belfast
BT12 7AL, Northern Ireland.
				
	 	 	-and-	 	 	 	 
		
	 (“the OEM”)
	 	 Xenogen Corporation
 860 Atlantic
Ave.
 Alameda, CA 94501

  
 WHEREBY IT IS AGREED AS
FOLLOWS: 
  

	 	1.	DEFINITION 

  
 1.1 In this Agreement where the context so admits: 
  

							
	 “Party”
	 	shall mean, as appropriate, either of the Manufacturer or the OEM, and “Parties” shall mean both Manufacturer and OEM.
		
	 “Products”
	 	shall mean the products manufactured by the Manufacturer specified in the First Schedule, including any products added to the First Schedule from time to time.
		
	 “Invoice Value”
	 	means the sums invoiced by the Manufacturer to the OEM in respect of any Products purchased by OEM, less any value added tax (or other taxes, duties or levies) and any amounts for
transport or insurance included in the invoice.
		
	 “Sale”
	 	shall include any supply by way of hire, purchase, credit sale or lease as well as outright sale and “sell” and “sold” shall be construed
accordingly.
		
	 “Trade Marks”
	 	means the trademarks actually used by the Manufacturer on, or in relation to, the Products at any time during this Agreement.

  

					
	Confidential	 	Page 3	 	July 26, 2002

 Andor Technology
Ltd.            Original Equipment Manufacturer Agreement 
  

							
	“Year of this Agreement”	 	means the period of 12 months from the date of this Agreement and each subsequent period (if any) of 12 months during the period of this Agreement.

  

	 	2.	TERM 

  
 2.1 This Agreement shall commence on 1st, October 2002 and shall continue (subject to same being terminated at any time in accordance with the provisions of clause 9 hereof) for a period of 24 months thereafter. 
  

	 	3.	RENEWAL 

  
 3.1 Not later than ninety (90) days prior to the expiry of this Agreement, the Parties shall meet to negotiate the terms of any subsequent
agreement, including the establishment of a Products “purchase forecast”. The Manufacturer will use the “purchase forecast” to set pricing and to establish lead times. Providing both Parties agree on acceptable terms, this
Agreement may be renewed for a further 12-month period. 
  

	 	4.	CANCELLATION OF PRIOR AGREEMENT/ENTIRE AGREEMENT 

  
 4.1 This agreement is in substitution for all prior agreements (if any) between the Manufacturer and the OEM relating to the Products.

  

	 	5.	PURCHASE ETC. OF PRODUCTS 

  
 5.1 The Manufacturer will manufacture, package and ship Products in accordance with the OEM’s purchase orders placed with the
Manufacturer. Such purchase orders shall specify the Product model number and description of the Product, quantity of the Product, specifications and requested delivery dates (each a “Purchase Order”). Requested delivery dates shall not be
less than eight (8) weeks in advance of the date of the “Purchase Order”. 
  
 5.2 The Manufacturer shall not be liable for any failure in the performance of any of its obligations under this agreement caused by
factors outside its control, consisting of acts of God, labor disputes or disturbances, material shortages or rationing, riots, acts of terrorism or war, governmental regulations or communication or utility failures. 
  
 5.3 Within 7 days of receipt of each “Purchase
Order”, the Manufacturer shall acknowledge its receipt and shall confirm a delivery date of specified Products to the OEM in writing (whether by e-mail, facsimile or other written form). The Manufacturer will promptly advise the OEM of any
possible variances from such confirmed delivery dates. If such variances exceed four (4) weeks, then OEM may cancel the Purchase Order without penalty. The Manufacturer shall notify the OEM in writing upon dispatch of Product. 
  

					
	Confidential	 	Page 4	 	July 26, 2002

 Andor Technology
Ltd.            Original Equipment Manufacturer Agreement 
  
 5.4 The Manufacturer shall take all reasonable actions required to fulfill “Purchase Orders”, and it shall use its reasonable
endeavours to despatch Products specified in the First Schedule within eight weeks of the Purchase Order received date. 
  
 5.5 The Manufacturer will manufacture, package and ship the Products in conformance with good business and manufacturing practices,
agreed-to specifications stated in the applicable Purchase Order and in accordance with any tests and specifications agreed in writing between the OEM and the Manufacturer. 
  
 5.6 The Manufacturer shall maintain all technical, quality control, shipping and other appropriate
documentation and records concerning the Products manufactured, packaged and shipped by the Manufacturer pursuant to this agreement and shall preserve same for a period of at least five years from the date of shipment. The Manufacturer shall not
destroy any such records without first giving the OEM thirty days prior written notice and an opportunity to take possession of such records. In any case, a copy of the appropriate documentation, as described above, will form part of each shipment
of Product to the OEM. 
  
 5.7 The price payable
by the OEM for Products shall be the price shown in respect of each particular Product as set out in the First Schedule hereto and as dispatched from the Manufacturer’s location at South Windsor, Connecticut. 
  
 5.8 All prices for Products are exclusive of any shipping
and handling charges or applicable sales tax or any new sales tax, for which the OEM shall be additionally liable as applicable to any dispatch made from the Manufacturer’s location at South Windsor, Connecticut. 
  
 5.9 The Manufacturer agrees to extend credit terms to the
OEM. Payment by the OEM shall be due on the 45th day after the Manufacturer issues an invoice to the OEM for those Products (“Payment Date”). Invoices will accompany Products when dispatched by Manufacturer and will list the applicable
Product serial numbers. 
  
 The Manufacturer
shall not be under any obligation to continue the manufacture of all or any of the Products, subject to the provisions of clause 9. The Manufacturer shall inform the OEM in writing of the intention to alter the specifications of the Products and
give six (6) months notice of any material or functional change in the Products. 
  
 5.11 All Products ordered by the OEM shall be packed for shipment and storage in accordance with the Manufacturer’s standard
commercial practice and will include all necessary Product documentation. Special packaging requirements will be disclosed by the OEM and agreed to by the Manufacturer, taking into consideration any environmental, economic or other constraints and
influences. 
  
 5.12 All shipments and all
shipping and other charges shall be deemed correct unless Manufacturer receives from OEM, no later than thirty (30) days after OEM’s receipt of a 
  

					
	Confidential	 	Page 5	 	July 26, 2002

 Andor Technology
Ltd.            Original Equipment Manufacturer Agreement 
  
 given shipment of Products, a written notice specifying the shipment, the transfer order number, and the exact nature of the discrepancy between the
Purchase Order and the shipment or the exact nature of the discrepancy in the shipping or other charges, as applicable. Any Products supplied by Manufacturer under this Agreement which fail to conform to the Product specifications specified in the
applicable “Purchase Order” shall be subject to the provisions of Section 6 below. The OEM shall use commercially reasonable efforts to perform customary inspections of Product shipments in the normal course of its business. Any claim
regarding the failure of Products within a shipment to conform to the applicable specifications shall be submitted to Manufacturer promptly upon discovery, together with reasonable evidence of such nonconformity at the time of inspection.

  
 Prices for Products which may be added to the
First Schedule from time to time after the date of this Agreement shall be determined by the mutual agreement of the Parties and shall be set forth on an addendum to such First Schedule. 
  
 In the event that Manufacturer manufactures, markets or distributes, either on its own behalf or on behalf
of any other entity in the period of this agreement a product having similar functionality and intended for similar uses to compete in the same market as the OEM’s line of IVISTM Imaging Systems (a “System Product”) the Manufacturer agrees that OEM will
be entitled to purchase Products at the maximum discount indicated on the First Schedule attached hereto without the necessity of satisfying the volume levels required by the First Schedule for such discount. The Manufacturer further agrees that, in
such event the OEM will not be obligated to make any “reconciliation payments” as described in the First Schedule for the period of this agreement. 
  

	 	6.	CUSTOMER AND GUARANTEE SERVICE 

  
 6.1 Manufacturer hereby warrants that any Product delivered hereunder: (a) upon receipt by OEM will meet the specifications therefore; (b)
for a period of *** after delivery to OEM will meet the specifications therefore and perform in accordance with such specifications; and (c) for a period of *** after delivery to a customer of OEM, will maintain a sufficient vacuum seal so as to
permit CCD cooling and operation in accordance with specifications applicable at the time of delivery to OEM. 
  
 6.2 In the case of a claim made under the Manufacturer’s standard warranty provided in Section 6.1 above, the Manufacturer will
promptly repair (or arrange for the repair) or replace the defective Product (or component thereof) at its own cost and expense and including any shipping and handling costs after such defective Product (or component thereof) has been returned to
the Manufacturer, subject to the Manufacturer confirming that the Product is defective and that the claim under the warranty is valid. 
  

					
	Confidential	 	Page 6	 	July 26, 2002

  

	***	Confidential treatment requested 

  

 Andor Technology
Ltd.            Original Equipment Manufacturer Agreement 
  
 6.3 The Manufacturer will repair or replace defective Products within four (4) weeks of receipt of Products that are within warranty and
six (6) weeks from receipt of purchase order for repair of Products that are out of warranty. 
  

	 	7.	MANUFACTURER’S FURTHER OBLIGATIONS 

  
 The Manufacturer hereby agrees that it: 
  
 7.1 Will assist the OEM (as and when requested by the OEM) in providing customers with technical support by enabling OEM to have direct
access to the Manufacturer by means of telephone and Internet E-mail during normal business hours. 
  
 7.2 Will provide to the OEM such training and technical assistance in relation to Products as may be reasonably necessary to enable the
OEM to perform its obligations hereunder. 
  
 7.3
May from time to time advise the OEM in writing of projects under consideration by the Manufacturer that the Manufacturer believes, to the best of its knowledge, may be of interest to, and are applicable to, the OEM’s Market, and which the
Manufacturer considers may be best addressed through the business of the OEM. The OEM shall have non-exclusive right to consider such proposals and to choose to fund such projects in a reasonable period of time subject to the terms of this
Agreement, and the parties will negotiate in good faith such economic and other terms in relation to such projects; provided that the Manufacturer shall be entitled at any time to agree the funding of any such project with any third party.

  
 7.4 Will ensure that the OEM receives the
same level of service, pricing and priority on Purchase Orders and Products as enjoyed by other similarly situated customers of the Manufacturer. 
  

	 	8.	OEM’S FURTHER OBLIGATIONS 

  
 The OEM shall; 
  
 8.1 Maintain Manufacturer’s confidential information in OEM’s possession in accordance with the terms of the Non-Disclosure
Agreement between the parties, dated March 22, 2002. 
  
 8.2 Upon the expiry of this Agreement (unless the Parties have agreed to a subsequent agreement in accordance with clause 3 above) return to the Manufacturer all confidential information in the possession of the OEM (whether written,
computer readable or otherwise) relating to the Manufacturer and/or the Products. 
  

					
	Confidential	 	Page 7	 	July 26, 2002

 Andor Technology
Ltd.            Original Equipment Manufacturer Agreement 
  
 8.3 To provide the Manufacturer in writing each calendar quarter a non-binding forecast of the number of Products it anticipates
purchasing during each of the following six (6) calendar months. 
  
 8.4 Not in any way use or claim any right In any of the Trade Marks or in any other intellectual property of the Manufacturer except as required for the purposes of this Agreement. 
  

	 	9.	TERMINATION 

  
 9.1 Without prejudice to any other remedies that either Party may have against the other, either Party shall have the right to terminate
this Agreement forthwith in any of the following events: 
  
 (a) if the other Party is in material breach of any of its obligations under this Agreement and fails to remedy such breach within 28 days of receipt by that other Party of written notice specifying the nature of the
breach; 
  
 (b) if the other Party: (i) shall
cease to carry on its business; (ii) becomes insolvent, however evidenced, or makes an assignment for the benefit of creditors; (iii) files a petition seeking relief under any statute now or hereafter in effect affording relief to debtors, or any
such application or petition is filed against such other Party, which application or petition is not dismissed or withdrawn within forty-five (45) days from the date of its filing; (iv) has a receiver appointed for such other Party or for all or a
substantial part of the assets of such other Party and such receivership proceedings are not dismissed within forty-five (45) days after such receiver’s appointment; or (v) commencement by such other Party of liquidation, dissolution or
winding-up proceedings, or the commencement against such other Party of a proceeding to liquidate, wind-up or dissolve such other Party, which proceeding is not dismissed within forty-five (45) days. 
  
 9.2 If the Manufacturer ceases to manufacture the Products
entirely and provides the OEM with 90 days written notice thereof, this Agreement shall terminate automatically; provided that Manufacturer will remain obligated to fulfil any Purchase Orders submitted by the OEM within 60 days after its receipt of
the foregoing notice. 
  
 9.3 The expiration or
earlier termination of this agreement shall not: 
  

	 	•	affect the provisions of clauses 6.1, 6.2, 6.3, 8.1, 8.2, 8.4, 9.2, 9.3, 10, 12, 13 and 14; 

  

	 	•	prejudice the rights and remedies of either Party against the other in respect of any prior breach of covenant or condition; or 

  

					
	Confidential	 	Page 8	 	July 26, 2002

 Andor Technology
Ltd.            Original Equipment Manufacturer Agreement 
  

	 	•	release either Party from any liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such
termination. 

  

	 	10.	TITLE TO GOODS 

  
 10.1 Notwithstanding anything herein to the contrary contained until payment has been made for same in full by the OEM to the Manufacturer
title to Products sold hereunder shall not pass to the OEM (and so that until such payment the OEM shall be deemed to be a bailee only of such goods) but risk therein shall be deemed to have passed to the OEM upon delivery. 
  

	 	11.	AMENDMENTS 

  
 No variations in the terms of this Agreement shall be valid unless in writing and signed by or on behalf of the parties hereto.

  

	 	12.	HEADINGS 

  
 12.1 The Headings are inserted for convenience only and shall not affect the interpretation of this Agreement. 
  
 12.2 This agreement embodies the entire understanding of the
parties in respect of the matters contained or referred to in it and there are no promises, terms, conditions or obligations (oral or written, express or implied) other than those contained in this agreement. 
  
 12.3 Any notice given under this agreement shall be in
writing and may be served: 
  

	 	•	by registered or recorded delivery mail; 

  

	 	•	by telex or facsimile transmission (the latter confirmed by telex or post); or 

  

	 	•	personally to the other Party at its above mentioned address. 

  
 All notices shall be effective as of the date received by the addressee. 
  
 12.4 This Agreement is personal to the Parties and no Party may assign or dispose of its rights and/or
obligations under it without the other Party’s prior written consent; provided, that each Party may assign this Agreement to a person or entity that acquires all or substantially all of the business or assets of that Party (or that portion
thereof to which this Agreement pertains), in each case whether by merger, acquisition, operation of law or otherwise, provided that such assignee agrees in writing to be bound by the terns and conditions of this Agreement. Subject to the foregoing,
the provisions of this Agreement shall apply to and bind the successors and permitted assigns of the Parties. 
  

					
	Confidential	 	Page 9	 	July 26, 2002

 Andor Technology
Ltd.            Original Equipment Manufacturer Agreement 
  
 12.5 Should any section, or portion thereof, of this Agreement be held invalid by reason of any law, statute or regulation existing now or
in the future in any jurisdiction by any court of competent authority or by a legally enforceable directive of any governmental body, such section or portion thereof shall be validly reformed so as to approximate the intent of the Parties as nearly
as possible and, if such reform is not possible, shall be deemed divisible and deleted with respect to such jurisdiction, but the Agreement shall not otherwise be affected. 
  
 The relationship of OEM and Manufacturer established by this Agreement is that of independent contractors.
Nothing in this Agreement shall be construed to create any other relationship between OEM and Manufacturer. Neither Party shall have any right, power or authority to assume, create or incur any expense, liability or obligation, express or implied,
on behalf of the other. 
  

	 	13.	CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999 

  
 13.1 No term of this agreement is enforceable pursuant to the Contracts (Rights of Third Parties) Act 1999 by any person who is not a
party to it. 
  

	 	14.	Nature of Agreement 

  
 14.1 If OEM and Manufacturer are unable to resolve any dispute between them, either OEM or Manufacturer may, by written notice to the
other, have such dispute referred to the Chief Executive Officers (or equivalent position) of OEM and Manufacturer, for attempted resolution by good faith negotiations within thirty (30) days after such notice is received. 
  
 Any disputes, controversies or claims that cannot be settled
amicably by agreement of the Parties pursuant to Section 14.1 above shall be finally settled by binding arbitration in the manner described In this Section 14.2. The arbitration shall be conducted pursuant to the commercial arbitration rules of the
International Chamber of Commerce then in effect. Notwithstanding those rules, the arbitration shall be held in New York, New York by a single arbitrator, provided that at the request of any Party, the arbitration shall be conducted by a panel of
three (3) arbitrators, with one (1) arbitrator chosen by each of OEM and Manufacturer, and the third appointed by the other two (2) arbitrators. In any event, the arbitrator(s) selected in accordance with this Section 14.2 are referred to herein as
the “Panel” and shall be comprised of independent experts with experience in the field of the dispute. The Parties shall share equally the fees of the Panel. Each Party shall bear the costs of its own attorneys’ and experts’
fees; provided that the Panel may, in its discretion award the prevailing Party all or part of the costs and expenses incurred by the prevailing Party in connection with the arbitration. Judgment upon the award may be entered in any court having
jurisdiction, or application may be made to such court for judicial acceptance of the award and/or an order of enforcement, as the case may be. No Party shall initiate arbitration hereunder unless it has attempted first to resolve the dispute in
accordance with Section 14.1. 
  

					
	Confidential	 	Page 10	 	July 26, 2002

 Andor Technology
Ltd.            Original Equipment Manufacturer Agreement 
  
 IN WITNESS whereof this Agreement has been executed in manner hereinafter appearing the day and year first above written. 
  
 SIGNED on behalf of the Manufacturer in the presence of: 
  

	
	 /s/    Illegible        

	

	 Authorized Director

  
 SIGNED on behalf of the
OEM in the presence of: 
  

	
	 /s/    Pamela Reilly Contag      

	

	 Authorized Director

  

					
	Confidential	 	Page 11	 	July 26, 2002

  

 Andor Technology
Ltd.            Original Equipment Manufacturer Agreement 
  
 First Schedule 
  

													
	 	  	 	  	 	  	 	  	 OEM Disc.
Pricing/
 Unit Volume2

	Item #

	  	Andor Part #

	  	 Description

	  	Unit Price

	  	***

	  	***

	  	***

							
	1	  	DW-434-BV	  	 CCD Camera head with the following features:
 >
Marconi 47-10 Black illuminated sensor
 > 1024x1024 pixels (13.5 micron sq.)
 > Hard metal vacuum seal w/ 5 yr. Warranty
 > Min. cooling to – 75 air ( – 85 w/water)
	  	***	  	***	  	***	  	***
							
	2	  	Cci-010	  	 Camera controller card with the following features:
 >
Dual 16 bit A/D converters
 > 1, 2, 16, 32 usec readout rates
 > TE cooling control
 > 12C communications buss
	  	***	  	***	  	***	  	***
							
	3	  	SDK-CCD	  	Software developers kit	  	***	  	***	  	***	  	***
							
	4	  	OEM-CAMP	  	 Cooler amplifier PCB:
 Single PCB power supply for
increased TE performance
	  	***	  	***	  	***	  	***
					
	Total System price	  	***	  	***	  	***	  	***
							
	*	  	PS-155	  	External cooler power supply	  	***	  	***	  	***	  	***
	*	  	SP-shutter	  	Shutter and mounting flange	  	***	  	***	  	***	  	***

  
 Notes: 
  

	1	Manufacturer acknowledges that OEM intends to submit Purchase Orders for greater than *** Systems (as indicated in the above table) during the first two (2) Years of this Agreement,
and Manufacturer agrees that OEM need only pay the *** discounted price shown in column “3” above for invoiced Products. However, in the event that, after the end of the first two (2) Years of this Agreement, OEM has not submitted Purchase
Orders for at least *** Products, then Manufacturer may require OEM to make a “reconciliation payment” to the Manufacturer as follows: 

  

					
	Confidential	 	Page 1	 	July 26, 2002

  

	***	Confidential treatment requested 

  

 Andor Technology
Ltd.            Original Equipment Manufacturer Agreement 
  

	 	a.	If OEM submits Purchase Orders for at least ***, Products during such two (2) Years of this Agreement, then OEM shall be entitled to the *** discount price shown in column
“2” for all invoiced Products and shall pay Manufacturer the aggregate difference between the discounted price paid by OEM and the discounted price it was entitled to as calculated above. 

  

	 	b.	If OEM submits Purchase Orders for less than *** Products during such two (2) Years of this Agreement, then OEM shall be entitled to the *** discount price shown in column
“1” for all invoiced Products and shall pay Manufacturer the aggregate difference between the discounted price paid by OEM and the discounted price it was entitled to as calculated above. 

  

	 	c.	If OEM submits Purchase Orders for at least ***, Products during such two (2) Years of this Agreement, then OEM shall be entitled to the *** discount price shown in column
“2” for all invoiced Products and shall pay Manufacturer the aggregate difference between the discounted price paid by OEM and the discounted price it was entitled to as calculated above. 

  

	 	d.	Notwithstanding any other provision of this First Schedule, if OEM submits Purchase Orders for at least *** Products during such two (2) Years of this Agreement, then OEM shall be
entitled to the *** discount price shown in column “2” for all invoiced Products. 

  

	 	e.	The foregoing reconciliation payments shall be due within thirty (30) days of OEM receiving Manufacturers invoice for such amount after the end of the applicable time period.

  

	2.	OEM and Manufacturer agree to review OEM’s Purchase Order quantity at the end of the first Year of this Agreement. 

  

	3.	It is understood and agreed that the five (5) cameras ordered by OEM on Purchase Order #4050bo on April 3, 2002 apply toward the order volumes discussed in this First Schedule and
toward OEM’s fulfillment of the order quantities necessary to receive the price discounts permitted by this First Schedule during the first two (2) Years of this Agreement. 

  

					
	Confidential	 	Page 2	 	July 26, 2002

  

	***	Confidential treatment requestedSupply Agreement

 Exhibit 10.23 
  
 [CONFIDENTIAL TREATMENT REQUESTED. PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE
COMMISSION.] 
  
 D-LUCIFERIN SUPPLY AGREEMENT

  
 This D-Luciferin Supply Agreement (the
“Agreement”), effective as of December 31, 2001 (the “Effective Date”), is made by and between Biosynth International, Inc., an Illinois corporation, having a place of business at 1665 West Quincy Avenue,
Suite 155, Naperville, IL 60540 (“Biosynth”), and Xenogen Corporation, a California corporation, having a place of business at 860 Atlantic Avenue, Alameda, CA 94501 (“Xenogen”) (each a “Party,”
collectively “Parties”). 
  
 BACKGROUND

  
 A. Xenogen has expertise in the development and use of
imaging systems and bioluminescent reporter assays for the imaging of living cells, organisms and transgenic animals. 
  
 B. Biosynth is in the business of developing and manufacturing chemical compounds, including D-Luciferin, potassium salt (“Luciferin”).

  
 C. Xenogen wishes to purchase from Biosynth, and Biosynth
wishes to supply to Xenogen, Luciferin for use in Xenogen’s imaging systems and bioluminescent reporter assays. 
  
 NOW, THEREFORE, for and in consideration of the covenants, conditions and undertakings hereinafter set forth, Xenogen and Biosynth each agree as follows:

  
 ARTICLE 1 
  
 SUPPLY OF LUCIFERIN 
  
 1.1 Terms and Conditions. All supply of Luciferin by Biosynth to
Xenogen shall be subject to the terms and conditions of this Agreement. ANY ADDITIONAL OR INCONSISTENT TERMS OR CONDITIONS IN ANY ORDER OR ACKNOWLEDGEMENT GIVEN OR RECEIVED REGARDING THE SUBJECT MATTER OF THIS AGREEMENT SHALL HAVE NO EFFECT AND SUCH
TERMS AND CONDITIONS ARE HEREBY EXPRESSLY EXCLUDED. 
  
 1.2
Supply. Subject to the terms and conditions of this Agreement, Biosynth shall supply Xenogen with its requirements for Luciferin, and Xenogen agrees to purchase from Biosynth all of its requirements for Luciferin. 
  
 1.3 Orders. All orders for Luciferin hereunder shall be made by means
of written purchase order to Biosynth at the address or fax number designated for notices in Section 5.7 below and shall specify the requested delivery date. 
  
 1.4 Pricing. 
  
 1.4.1 Price. Biosynth will provide Luciferin to Xenogen at a fixed price of  ***  during the term of this
Agreement. 
  
 *** Confidential treatment requested 
  

 1.4.2 Competitive Pricing. If, after the Effective Date, Xenogen is offered
Luciferin of equal quality at a lower price than is available under this Agreement, then Xenogen will notify Biosynth of such offer and give Biosynth thirty (30) days to reduce the price. If Biosynth is unable to match such competitive price, then,
notwithstanding Section 1.2 above, Xenogen shall be free to purchase Luciferin from the alternate source. 
  
 1.5 Shipping. All Luciferin shipped to Xenogen pursuant to the terms of this Agreement shall be packaged in one (1) gram packs suitable for air
shipment, marked for shipment to the destination point indicated in Xenogen’s purchase order, and shipped FOB (as defined under California law) place of shipment. All shipments will be insured and sent FEDEX 2nd day service unless Xenogen requests overnight shipment. All freight, insurance and other shipping expenses from the point of shipment shall be borne
by Xenogen. With respect to exact shipping dates of Luciferin, Biosynth shall use its best efforts to ship the requested quantities of Luciferin on the dates specified in Xenogen’s purchase order. 
  
 1.6 Invoicing/Payment. Biosynth shall submit an invoice to Xenogen
upon shipment of Luciferin ordered by Xenogen hereunder. All invoices shall be sent to Xenogen’s address for notices hereunder or such other address as designated by Xenogen in writing, and each such invoice shall state Xenogen’s aggregate
and unit price for Luciferin in a given shipment, plus any insurance, taxes or other costs incident to the transfer or shipment initially paid by Biosynth but to be borne by Xenogen hereunder. Payment for all Luciferin purchased hereunder by Xenogen
shall be due net thirty (30) days from date of Biosynth’s invoice. 
  
 1.7 Inspection/Rejection. 
  
 1.7.1 Product Inspection. Xenogen shall, upon receipt of each shipment, perform customary inspection. Any claim regarding the failure of such shipment to conform to the applicable Specifications shall be submitted to Biosynth upon
discovery, together with reasonable evidence of such nonconformity. Any Luciferin supplied by Biosynth under this Agreement that fails to conform to the applicable Specifications shall be subject to the provisions of Section 1.10.2. 
  
 1.7.2 Discrepancies. All shipments, and all shipping
and other charges, shall be deemed correct unless Biosynth receives from Xenogen a written notice specifying the shipment, the purchase order number, and the exact nature of the discrepancy between the order and the shipment, or the exact nature of
the discrepancy in the shipping or other charges, as applicable. 
  
 1.8 Reserves. Biosynth shall maintain a  ***  reserve of Luciferin in Naperville, IL for use by Xenogen in the event Biosynth is unable to produce quantities of Luciferin sufficient to meet Xenogen’s
requirements. Biosynth further agrees that Biosynth AG will reserve an additional  ***  supply of Luciferin for Xenogen in Staadt, Switzerland for use by Xenogen in the case of a failure in supply. For purposes of this Section
1.8, a  ***  reserve of Luciferin shall initially be defined as  ***, which amount may be adjusted periodically upon request by Xenogen to accommodate changes in Xenogen’s projected requirements for Luciferin.

  
 *** Confidential treatment requested 
  

 -2- 

 1.9 *** 
  
 1.10 Product Warranty. 
  
 1.10.1 Product Warranty. Subject to the terms and conditions of this Agreement, Biosynth represents and warrants that all Luciferin
supplied by Biosynth to Xenogen under this Agreement shall (i) comply, at the time of shipment to Xenogen or its designee, with the specifications established by Biosynth and attached hereto as Exhibit A; and (ii) meet Xenogen’s requirements
for performance in Xenogen imaging systems and bioluminescent reporter assays (collectively “Specifications”). 
  
 1.10.2 Remedy for Non-conformance. In the event that any Luciferin fails to comply with the warranty set forth in Section 1.10.1
above, then Biosynth shall, at Xenogen’s sole election, either (i) deliver, at Biosynth’s own cost (including freight and insurance), replacement quantities of such Luciferin to Xenogen as soon as practicable, but in all cases within
thirty (30) days of Biosynth’s receipt of notice of such nonconforming shipment; or (ii) credit Xenogen’s account for the amount paid for such Luciferin. Biosynth shall give Xenogen written instructions as to how Xenogen should, at
Biosynth’s expense, dispose of any non-conforming Luciferin. 
  
 1.11 Quality and Quality Control. All Luciferin supplied by Biosynth shall be manufactured using reasonable manufacturing and record keeping procedures. Prior to each shipment of Luciferin, Biosynth shall perform reasonable
quality control procedures and inspections in an effort to confirm that such Luciferin conforms fully with the Specifications. Each shipment of Luciferin shall be accompanied by a materials safety datasheet and a signed certificate of analysis
indicating the lot number(s) of the Luciferin included in such shipment and describing all current requirements of the Specifications together with the results of tests performed and a statement certifying that the Luciferin in such shipment has
been manufactured, controlled and released in accordance with this Section 1.11. 
  
 1.12 Failure to Supply. If for two (2) consecutive months Biosynth fails to fulfill Xenogen’s orders for Luciferin according to the terms of this Agreement, such failure shall be considered a material
breach of this Agreement. In the event of such breach, notwithstanding any other remedies that may be available to Xenogen under this Agreement, Xenogen’s purchase obligations under Section 1.2 above shall be immediately suspended and Xenogen
shall be free to obtain its requirements for Luciferin from an alternate source. 
  
 ARTICLE 2 
  
 TRADEMARKS 
  
 2.1 Use. Subject to
Section 2.1, Xenogen grants to Biosynth a nonexclusive right to use the trademarks, marks, trade names and logos that Xenogen may adopt from time to time (“Xenogen Marks”) to manufacture product packaging, product inserts and labels for
the Luciferin supplied to Xenogen under this Agreement. 
  
 *** Confidential
treatment requested. 
  

 -3- 

 2.2 Approval of Representations. Biosynth will design the product packaging, product inserts
(including the certificate of analysis) and labels for the Luciferin supplied to Xenogen under this Agreement using artwork for the Xenogen Marks to be supplied by Xenogen. Design of the labels, product packaging and product inserts will be per
mutual agreement, provided that Biosynth shall obtain Xenogen’s written consent with respect to both the design and production costs before proceeding with production of the labels, product packaging and product inserts. In addition, Biosynth
shall follow the instructions issued by Xenogen from time to time for the purpose of protecting the standards of quality established for the goods and services sold under the Xenogen Marks. 
  
 ARTICLE 3 
  
 INDEMNIFICATION 
  
 3.1 Indemnification of Xenogen. Biosynth shall indemnify and hold
harmless each of Xenogen and its affiliates, and the directors, officers, and employees of Xenogen and of such affiliates, and the successors and assigns of any of the foregoing (the “Indemnitees”), from and against any and all
liabilities, damages, settlements, claims, actions, suits, penalties, fines, costs or expenses (including, without limitation, reasonable attorneys’ fees and other expenses of litigation) incurred by any Indemnitee, based upon a claim of a
third party arising from or occurring as a result of: (a) breach of the product warranty in Section 1.10 by Biosynth; or (b) the negligence or willful misconduct of Biosynth in the performance of its obligations under this Agreement. 
  
 ARTICLE 4 
  
 TERM AND TERMINATION 
  
 4.1 Term. Unless terminated earlier pursuant to this Article 4, the
term of this Agreement shall commence on the Effective Date and continue in full force and effect for a period of three (3) years. Thereafter, the Parties may extend the term by mutual written agreement. 
  
 4.2 Termination for Cause. In the event of a material breach of
this Agreement, the nonbreaching Party shall be entitled to terminate this Agreement by written notice to the breaching Party, if such breach is not cured within sixty (60) days after written notice is given by the nonbreaching Party to the
breaching Party specifying the breach. 
  
 4.3 Effect of
Termination. 
  
 4.3.1 No Release.
Termination of this Agreement for any reason shall not release either Party hereto from any liability which at the time of such termination has already accrued to the other Party. Without limiting the foregoing, no payment that became payable prior
to termination or expiration of this Agreement shall be affected by such termination or expiration of the Agreement. Rather, such payments shall remain payable after termination or expiration in accordance with the terms and conditions of this
Agreement that were in effect immediately prior to the date of termination or expiration. 
  

 -4- 

 4.3.2 Survival. Articles 3 and 5 and Sections 1.10 and 4.3 shall survive any
expiration or termination of this Agreement. All other provisions of this Agreement shall terminate and have no further force or effect. 
  
 ARTICLE 5 
  
 GENERAL 
  
 5.1 Article and Section Headings, Language and Construction. The article and section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement. All references in this Agreement to “Articles,” “Sections” and “Exhibits” refer to the articles, sections and exhibits of this Agreement. The words “hereof,”
“herein” and “hereunder” and other words of similar import refer to this Agreement as a whole and not to any subdivision contained in this Agreement. The words “include” and “including” when used herein are
not exclusive and mean “include, without limitation” and “including, without limitation,” respectively. This Agreement has been negotiated by the Parties and their respective counsel. Accordingly, this Agreement will be
interpreted fairly in accordance with its terms and without any strict construction in favor of or against either Party. 
  
 5.2 Governing Law; Venue. This Agreement and any dispute arising from the performance or breach hereof shall be governed by and construed and
enforced in accordance with the laws of the state of California, without reference to conflicts of laws principles. The exclusive venue of any dispute arising out of or in connection with the performance or breach of this Agreement shall be the
California state courts located in Alameda County, California or the or U.S. district court for the Northern District of California, and the Parties hereby consent to the personal jurisdiction of such courts. 
  
 5.3 Independent Contractors. The relationship of Biosynth and Xenogen
established by this Agreement is that of independent contractors. Nothing in this Agreement shall be construed to create any relationship other than independent contractors. Neither Party shall have any right, power or authority to assume, create or
incur any expense, liability or obligation, express or implied, on behalf of the other. 
  
 5.4 Compliance with Laws. Notwithstanding anything to the contrary contained herein, all rights and obligations of Xenogen and Biosynth are subject to prior compliance with, and each Party shall comply with,
all applicable laws, regulations, and orders, including obtaining all necessary approvals required by the applicable agencies of the of the United States government. 
  
 5.5 Modification. No amendment or modification of any provision of this Agreement shall be effective unless in
writing signed by all Parties hereto. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and signed by all
Parties. 
  
 5.6 Severability. If any provision hereof
should be held invalid, illegal or unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute 
  

 -5- 

 provision that most nearly reflects the original intent of the Parties and all other provisions hereof shall remain in
full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability shall not affect the validity,
legality or enforceability of such provision in any other jurisdiction. 
  
 5.7 Notices. Any notice or other communication required by this Agreement shall be made in writing and given by (i) prepaid, first class, certified mail, return receipt requested, (ii) facsimile, or (iii) overnight courier, and shall
be deemed to have been served on the date received by the addressee at the following address or such other address as may from time to time be designated to the other Party in writing: 
  
 If to: Biosynth 
  
 Biosynth International, Inc. 
 1665 West
Quincy Avenue, Suite 155 
 Naperville, IL 60540 
  
 Attn:
                                       

Telefax: (        )
                      
  
 If to: Xenogen 
  
 Xenogen Corporation. 
 860 Atlantic Avenue

 Alameda, CA 94501 
  
 Attn:
                                       

Telefax: (        )
                      
  
 With a copy to: 
  
 Wilson Sonsini Goodrich & Rosati 
 650
Page Mill Road 
 Palo Alto, CA 94304-1050 
 Attn: Kenneth A. Clark, Esq. 
 Telefax: (415) 493-6811 
  
 5.8 Entire Agreement. The Parties hereto acknowledge that this
Agreement and the attached exhibit, set forth the entire agreement and understanding of the Parties as to the subject matter hereof, and supersedes all prior and contemporaneous discussions, agreements and writings in respect hereto including
without limitation the previous D-Luciferin, potassium salt supply agreement dated February 5, 1999. 
  

 -6- 

 5.9 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an
original, but both of which together shall constitute one and the same instrument. 
  
 IN WITNESS WHEREOF, the Parties hereto have caused their duly authorized representatives to execute this Agreement. 
  

									
	 XENOGEN CORPORATION
	 	 	 	 BIOSYNTH, INTERNATIONAL INC.

			
	 (“Xenogen”)
	 	 	 	 (“Biosynth”)

					
	 By:
	 	/s/    Illegible	 	 	 	By:	 	/s/    Illegible 
	 	 	
	 	 	 	 	 	

	 Name:
	 	 	 	 	 	 Name:
	 	 
	 	 	
	 	 	 	 	 	

	 Title:
	 	 	 	 	 	 Title:
	 	 
	 	 	
	 	 	 	 	 	

  

 -7- 

 EXHIBIT A 
  

LUCIFERIN SPECIFICATIONS 
  

	 Product 
	 D-Luciferin potassium salt 

  

	 	 [4.5-Dihydro-2-(hydroxy-2-benzothiazotly)-4-thiazolecarboxylic acid potassium salt] 

  

	 Molecular Formula 
	 C11H7N2O3S2K 

  

	 Molecular Weight 
	 318.42 

  

	 Appearance 
	 Yellow powder 

  

	 Solution 
	 Yellow clear (1% in water) 

  

	 Elemental Analysis 
	 Maximum 0.3% deviation from the theoretical values 

  
 TLC Analysis 

	             Plate 
	 Silica gel 60 (Merck-Darmstadt #5554) 

	             Spotting Solution 
	 50 mg in 5 ml water (2 μl spotted) 

	             Solvent System 
	 ethanol/ammonia 20:1 (v/v) 

	             Detection 
	 UV 254 nm 

  

	 UV 
	 c = 0.01 mg/ml (0.5 M sodium carbonate, pH 11.5) 

	 	 lmax 1 : 385.1 nm e1: 3 17.9391 Mol-1·
cm-1 

	 	 lmax 2 : 274.2 nm e2: 3 6.6661 Mol-1·
cm-1 

  

	 IR 
	 consistent with assigned structure 

  

	 Other 
	 packaged in 1 gram packs 

  

	 	 To be supplied with Certificate of Analysis (complete with lot number and signature) and Material Safety Data Sheet 

 

 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}]]